Pharmacoepidemiology of antibacterials use for nosocomial infections

Introduction. Antibacterial resistance of nosocomial infectious agents is a serious problem. It makes a choice of therapy complicated and worsens the prognosis of the disease significantly. Purpose of the study. The purpose of the study was the pharmacoepidemiological analysis of antibacterial use as a treatment for infections caused by multidrug-resistant pathogens. Material and methods. A retrospective study of medical records was conducted for hospitalized patients at the State Budgetary Institution “City Clinical Hospital named after S.S. Yudin DZM” in 2019–2021. Antibacterial therapy in hospital settings against pathogens of the ESKAPE group was analyzed and the resistance of the detected pathogens was determined. Results. 226 confirmed clinical cases of infection were analyzed. Results of 1422 microbiological studies were studied to determine the resistance of the detected pathogens. The structure of 562 prescriptions of drugs of the group J01 “Antibacterial drugs for systemic use” was studied. In 2020 the total volume of consumption of systemic antibacterials amounted for 85594 DDD. The DU-90% segment by the number of DDDs made up five drugs – meropenem, polymyxin B, tigecycline, amikacin and ampicillin/sulbactam. The intensity of drug consumption was also expressed in DDD/100 bed days. The most prescribed empirically systemic antibiotics for infections treatment have become the group of β-lactam drugs in combination with β-lactamase inhibitors and carbapenems. Tigecycline, polymyxin B and carbapenems are the main drugs for targeted treatment of nosocomial infections at the multidisciplinary hospital of the State Budgetary Institution “City Clinical Hospital named after S.S. Yudin DZM”.